Changes By Action Taken: Following additions are recommended approved by Committee. Additions Comments Effective Date
|
|
- Eugene Reynolds
- 5 years ago
- Views:
Transcription
1 Pharmacy Update: P&T Highlight The following is a summary of the actions taken at the Aetna Medicaid Pharmacy & Therapeutics Committee meeting(s) in 4 th Quarter Changes By Action Taken: Following additions are recommended approved by Committee Additions Comments Effective Date Olopatadine 0.1% soln Add with ST via ketotifen gtts/ 2/1/2017 QLL #1 bottle /25days Savella Add with Step via duloxetine 2/1/2017 Chlorzoxazone QLL 2/1/2017 Orphenadrine QLL 2/1/2017 Imbruvica PA/ QLL 4 caps/day 2/1/2017 Gilenya PA 2/1/2017 Tecfidera PA 2/1/2017 Auryxia Step via calcium acetate 2/1/2017 Apriso 2/1/2017 Viokace 2/1/2017 Xarelto PA 2/1/2017 Zarxio PA 2/1/2017 Breo Ellipta QLL 2/1/2017 Zepatier PA 2/1/2017 PA Prior Auth Required QLL Quantity Limit Applies ST Step Therapy Requirements exist Deletions Comments Effective Date Diltiazem ER/LA Tablets GF existing users, keep capsules 2/1/2017 Clomipramine GF existing users 2/1/2017 Imipramine CAPS* No GF, keep tabs as alternative 2/1/2017 Trazodone 300mg tab* No GF, permit 2 x 150mg tab 2/1/2017 Metaxalone 400mg and No GF 2/1/ mg* Carisoprodol 250mg* No GF 2/1/2017 Tizanidine GF existing users 2/1/2017 Clindamycin Aerosol* No GF 2/1/2017 Clindamysin/Benzoyl Peroxide No GF 2/1/2017 combo* Erythromycin/Benzoyl Peroxid combo* No GF 2/1/2017 Remove Sulfacetamide/Sulfur* Sulfacetamide 10% Lotion 2/1/2017 /Suspension Claravis No GF, Zenatane and Myorisan 2/1/2017 alts. TRETINOIN EM CRE 0.05%* No GF 2/1/2017 SALICYLIC AC GEL 6% * No GF, SALICYLIC AC CREAM 6% or Lotion 2/1/ Benzoyl Peroxide products:* No GF 2/1/2017
2 BP WASH LIQ 7% BPO CREAMY KIT 4% WASH and BPO GEL 4 Copaxone 20mg* No GF, use glatopa 20mg 2/1/2017 Farxiga* No GF 2/1/2017 Renvela/Renagel* No GF 2/1/2017 Delzicol, Dipentum, Pentasa GF existing users 2/1/2017 Amitiza GF existing users 2/1/2017 Pancreaze GF existing users 2/1/2017 Advair * No GF 2/1/2017 Symbicort* No GF 2/1/2017 Spiriva GF existing users 2/1/2017 Tudorza* No GF 2/1/2017 GF grandfathering PA Prior Auth Required ST Step Therapy Requirements exist Clinical Edit Changes Comments Date IUD Add QLL to 1 every 3 yrs 2/1/2017 Celecoxib Change step, remove tramadol 2/1/2017 as qualifying drug Elidel and Tacrolimus oint Remove smart Edit for auto-pa 2/1/2017 children, keep step for 2 corticosteroids Zenatane and Myorisan Step via oral abx/ QLL #60/30 2/1/ mg, 20mg, 30mg, (excludes 40mg, #03/30) TD Hard Edit on combo with topical retinoid PA Prior Auth Required QLL Quantity Limit Applies ST Step Therapy Requirements exist TD Therapeutic Duplication Classes Reviewed WITHOUT Changes Recommendations: Somatostatin Analogs Growth Hormone Synagis Cytokines and CAM Antagonists Viscosupplements
3 Summary of the Coverage Guidelines Changes: Guideline Summary of Changes Ampyra Updated age restriction and added QLL Cambia No changes Celecoxib Clarified duration to avoid use after CABG (within 14 days of CABG due to increased risk of MI/stroke) Removed history of ACS from exclusions (not a true contraindication) Removed NSAID-induced verbiage for gastritis (gastritis itself is a highrisk factor for GI events) Daraprim No changes Growth Hormone Added intrauterine growth as a non-covered indication Modafanil No changes Armodafanil Non-Stimulant No changes ADHD Ranexa No changes Somatostatin Added QLL s Analogs Synagis No changes Viscosupplements Added 3 new agents Hymovis, Genvisc and Gelsyn Anti-TNF s IL-17 Antagonists Integrin Antagonists Orencia Stelara Actemra Kineret Ilaris Xeljanz Combined all guidelines into 1 new guideline titled Cytokines and CAM Antagonists using previous anti-tnf guideline Criteria for RA: Removed criteria for patients with Early RA, high disease activity, and poor prognostic factors. Significant change to the 2015 ACR guideline for RA. DMARD s are recommended for all patients as the initial strategy. Criteria for AS: Removed requirement to use sulfasalazine first for patients with peripheral arthritis Updated AS guideline recommends anti- TNF s for all patients who have failed NSAIDs. Criteria for PsA: Removed MTX requirement for patients with active enthesitis or dactylitis EULAR updated PsA guideline recommends that patients with enthesitis or dactylitis should be progressed to an anti- TNF if they have not responded to NSAIDs (same recommendation as those with predominantly axial disease) Criteria for UC: Steroid-dependent: Removed mesalamine, balsalazide, and sulfasalazine as treatment requirements for patients who
4 have contraindications to 6-MP or azathioprine. If patients cannot take 6-MP or azathioprine, they should be allowed to receive an anti-tnf Criteria for Crohn s: Added Stelara (newly approved indication) Criteria for Hidradenitis: Added requirement that patients with severe disease must also failed an antibiotic per 2015 NICE guidelines. Previous version only required that patients with moderate disease have trial of antibiotics. Patients enrolled in the clinical trials for Humira had all previously received oral antibiotics. Added criteria for new indication: Uveitis: Patient is at least 18 years old Patient has intermediate, posterior, or panuveitis that is not caused by an infection Patient is currently taking an oral corticosteroid or has a contraindication to corticosteroids. (Humira has only been studied with prednisone for Uveitis.) Patient has had an inadequate response or intolerable side effects with at least 2 different steroid-sparing immunosuppressive medications such as methotrexate, azathioprine, mycophenolate, cyclosporine, or tacrolimus, or has contraindications to these agents. Added quantity limits Otezla Updated PsA criteria to be the same as the Cytokine/CAM Antagonist criteria Anticoagulants Injectable Agents Updated to align with CHEST update in February Added indication for treatment of patients who have recurrent VTE on oral anticoagulants Updated criteria for Fragmin and enoxaparin for acute VTE treatment in non-cancer patients LMWH should be used AFTER trial and failure of warfarin AND a target specific anticoagulant (e.g., Xarelto, Pradaxa, or Eliquis) Botulinum Toxins Updated criteria for Anal Fissures: Colony Stimulating Factors Trial of nitroglycerin ointment for 3 weeks AND one additional treatment Previously only required 1 treatment Added cumulative dose restriction for Botox based on package insert Added Zarxio as preferred agent Consolidated all of the key contraindications and requirements under the general authorization criteria for all agents and indications For primary prophylaxis of chemotherapy-induced neutropenia: Clarified the risk factors considered for patients receiving intermediate risk chemotherapy Added dosing table for all of the CSF agents
5 Erythropoiesis Stimulating Agents (ESA s) Added verbiage about preferred agents (Epogen will be preferred effective February 2017) Removed off-label indication for use in PEG/RBV induced anemia. AASLD no longer recommends PEG/RBV regimens for any genotype GnRH Analogs Added indication and criteria for Ovarian Cancer based on NCCN Hepatitis C Injectable Osteoporosis Prescribed by or in consultation with an oncologist Patient has failed or is intolerant to chemotherapy OR GnRH is used as post-operative management For CPP: removed age restriction; can be given as early as 1 year Added Zepatier as the formulary preferred and Epclusa as the non-formulary preferred Removed evidence of portal hypertension by MRI as exception to liver staging, no longer included on the AASLD Added clinical detail for cryoglobulinemia as it pertains to Hep C Moved Monitoring/Treatment plan to the top section with additional details regarding readiness and compliance and adherence, provider will need to attest on Fax form Consolidated Hep C table by each drug in the additional criteria section Zepatier Section Clarified for gt 1a with NS5A polymorphism 16 weeks of treatment is required Added Epclusa Section Covered for gt 2, 3, 5, and 6 without or with compensated cirrhosis Covered for gt 1-6 with decompensated cirrhosis (Zepatier is not indicated for decompensated cirrhosis) Included non-coverage for specific DDI s and for GFR < 30ml/min Harvoni Section Removed all other indications except for gt 1 and 4 with post liver transplant Sovaldi Section Removed all other indications except for HCC Daklinza section removed Added All other regimens will be considered on a case by case bases Non-Coverage Criteria Viekira/XR, Technivie, and Zepatier in patients with Child Pugh (B or C) Olysio, Daklinza, and Sovaldi used as monotherapy Use in combination with other DAA s unless indicated Any contraindications to any of the agents Removed the Peg-ineligible criteria, since Peg IFN is no longer recommended for treatment Updated clinical definition of osteoporosis to include fragility fracture Removed requirement for osteolytic lesions or high fracture risk for myeloma. All patients with MM should be offered zoledronic acid to prevent bone lesions Add QLL s
6 Interferons For hepatitis B: For Hairy-Cell Leukemia: Changed the ALT requirement from elevated to >2x ULN per the 2016 AASLD guideline update Changed initial approval duration for children from 16 weeks to 24 weeks per package insert Changed ANC value from <1000 to <1500 per NCCN Added discontinuation recommendation for nonresponders For Osteopetrosis: Removed age requirement per package insert For Condylomata: Added Alferon N product and it s appropriate approval durations Lyrica Spinal cord injury Post-herpetic neuralgia Removed all clinical criteria except diagnosis since there are no formulary alternatives for this indication Additional criteria failure of 3 months on gabapentin Multiple Sclerosis Updated to reflect formulary changes Weight Reduction Medications For non-preferred agents: Clarified that of the 2 formulary agents tried, at least one of the trials was with a preferred injectable Added new drug, Zinbryta to guideline Requires trial and failure of 2 formulary alternatives, one of which must be a preferred injectable Applicable to AZ and VA only (all other plans exclude weight loss drugs from coverage) Medical necessity clinical requirements remained the same to be eligible to receive any weight loss meds Identified preferred agents Sympathomimetics and OTC Alli are the first-preferred agents Belviq, Qsymia, and Contrave are the second-preferred agents Saxenda and Xenical are non-preferred Updated drug specific criteria For Belviq, Qsymia, and Contrave: Patient meets ONE of the following: Had an inadequate response, intolerable side effects, or a contraindication to Alli OR a sympathomimetic (e.g., phentermine, diethylpropion, benzphetamine); OR Had a good response to a
7 HIV For IL and NJ pilot Oncology Antineoplastic Agents New Guideline For Saxenda: For Xenical: sympathomimetic, however has taken the medication for the maximum recommended duration Patient has had inadequate efficacy or intolerable side effects with trials of at least 3 formulary agents OR has contraindications to all formulary agents Patient has had inadequate efficacy or intolerable side effects with a trial of Alli OTC at a dose of 120mg three times daily AND at least TWO other formulary agents OR has contraindications to all formulary agents Assures that HIV medications are prescribed to patients with an HIV diagnosis Formulary preferred medications require diagnosis only. Authorization Criteria for Truvada for pre-exposure prophylaxis (PrEP ) Patient is at continuous high risk for HIV infection Current (within 2 weeks) negative HIV antibody test Creatinine clearance > 60ml/min Patient is at least 18 years of age Authorization Criteria for Truvada for post-exposure prophylaxis (PeP) Exposure to HIV positive fluids within the last 72 hours Initial Authorization Durations: Renewal: Confirmed HIV dx: indefinite Truvada for PrEP: 14 weeks Truvada for PEP: 30 days only PrEP: 14 weeks and requires: Negative HIV antibody test result Creatinine clearance > 60ml/min Adherence confirmed by claims Member is under the care of an Oncologist Medication is prescribed for an FDA-approved indication OR for a medically accepted indication as noted in the following Compendia: o NCCN Drugs and Biologic Compendium or NCCN Clinical Practice Guidelines, category 1, 2a, or 2b. o Micromedex DrugDex o Clinical Pharmacology
8 The dose prescribed is within the FDA-approved range for the indication and patient specific factors (e.g., age, weight or BSA, renal function, liver function, drug interactions, etc) Requested medication is formulary preferred. Requests for non-preferred or non-formulary antineoplastics must meet ONE of the following: o Trials of formulary preferred agents for an adequate duration were not effective or were poorly tolerated o All other formulary preferred alternatives are contraindicated based on the member s other medical conditions or drug interactions o There are no formulary preferred medications for the patient s indication o Member has a genetic mutation that is resistant to the formulary preferred agents Medical records, lab results, test results, and clinical markers supporting the diagnosis and treatment are submitted with the request Member does not have any contraindications to the medication Member is not taking other medications that should be avoided with the requested drug based on the FDA-approved labeling Request is not for experimental/investigational use or for a clinical trial
Aetna Better Health of Illinois Medicaid Formulary Updates
October 2017 o DOXYLAMINE SUCCINATE 25mg-QL o DULOXETINE CAP 40MG DR-QL o GUANFACIN ER TABS (all strengths)-ql o TOBRAMYCIN NEBU SOLUTION- PA August 2017 Aetna Better Health of Illinois Medicaid 2017 Formulary
More information1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Humira (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationZepatier. Zepatier (elbasvir, grazoprevir) and Ribavirin. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Zepatier Page: 1 of 6 Last Review Date: March 18, 2016 Zepatier Description Zepatier (elbasvir,
More informationZepatier is contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh B or C) due to potential toxicity (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Zepatier Page: 1 of 6 Last Review Date: June 24, 2016 Zepatier Description Zepatier (elbasvir,
More informationHepatitis C Medications Hawaii PRIOR AUTHORIZATION REQUEST FORM
Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826. This form contains multiple pages. Please complete all pages to avoid a delay in our decision.
More informationDaklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 7 Last Review Date: June 24, 2016 Daklinza Sovaldi Description Daklinza
More informationDaklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.36 Subject: Daklinza Page: 1 of 8 Last Review Date: March 18, 2016 Daklinza Description Daklinza (daclatasvir)
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization MERC CARE PLA (MEDICAID) Humira (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More information3. Has the patient shown improvement in signs and symptoms of the disease? Y N
Pharmacy Prior Authorization MERC CARE (MEDICAID) Renflexis (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationJULY 2017 ADDITIONS. NP Thyroid 120mg NP Thyroid 15mg JUNE 2017 CHANGES
APRIL 2017 Ivermectin, Pin-X and Reeses (Pyrantel Pamoate) Selzentry 25mg and 75mg tablets Linzess 72 mcg capsule-with QLL Levalbuterol Tartrate Inhal Aerosol (Generic Xopenex HFA) with ST & QLL Jentadueto
More informationREQUEST FOR PRIOR AUTHORIZATION Hepatitis C Treatments
Fax completed form to: 866-940-7328 Prior Authorization Phone Number: 800-310-6826 IA Medicaid Member ID # Patient name Date of Birth Patient address Patient phone Provider NPI Prescriber name Phone Prescriber
More informationANTIDEPRESSANTS. Details. Step Therapy 2018 Last Updated: 8/21/2018
ANTIDEPRESSANTS EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL FETZIMA
More informationDrug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases
Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy
More informationRegulatory Status FDA-approved indication: Tysabri is an integrin receptor antagonist indicated for treatment of (1):
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.13 Subject: Tysabri Page: 1 of 6 Last Review Date: June 22, 2017 Tysabri Description Tysabri (natalizumab)
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease
More informationPrior Authorization Conditions for Approval of Humira (adalimumab) Website Form Submit request via: Fax
Prior Authorization Conditions for Approval of Humira (adalimumab) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Humira (adalimumab) require a prior
More informationHepatits C Criteria Direct Acting Antiviral Medications
Hepatits C Criteria Direct Acting Antiviral Medications Harvoni-Formulary PA required 1. Is the patient being treated for a funded condition by the Oregon Health Plan? 2. Does the member have a diagnosis
More informationImmune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
More information2. Does the patient have a diagnosis of ulcerative colitis or Crohn s? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH LOUISIAA (MEDICAID) Remicade (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationPharmacy Medical Necessity Guidelines: Hepatitis C Virus
Pharmacy Medical Necessity Guidelines: Hepatitis C Virus Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX)
More informationAddress: City: State: ZIP code: Inferferon Product Requested (Include Strength):
Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826. This form contains multiple pages. Please complete all pages to avoid a delay in our decision.
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir) PHARMACY PRI AUTHIZATION Hepatitis C Clinical Guideline Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir) Harvoni
More informationProtocol for daclatasvir (Daklinza ) Approved October 2015 (updated February 2018)
PREFERRED AGENTS: (See drug specific NOTES for exceptions.) Protocol for daclatasvir (Daklinza ) Approved October 2015 (updated February 2018) https://providers.amerigroup.com For genotype 1, Mavyret and
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
Program Number 2017 P 3041-8 Program Step Therapy Medications UnitedHealthcare Pharmacy Clinical Pharmacy Programs *Orencia (abatacept) *This step criteria refers to the subcutaneous formulation of abatacept
More information2017 United Healthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2055-10 Program Prior Authorization/Medical Necessity Medication Olysio (simeprevir) P&T Approval Date 4/2015, 11/2015, 8/2016,
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 6 Last Review Date: December 8, 2017 Orencia Description Orencia (abatacept)
More informationRegulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.12 Subject: Entyvio Page: 1 of 7 Last Review Date: September 20, 2018 Entyvio Description Entyvio
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Subject: Cimzia Page: 1 of 5 Last Review Date: December 8, 2017 Cimzia Description Cimzia (certolizumab
More informationTechnivie. Technivie (ombitasvir, paritaprevir, ritonavir) and Ribavirin. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Technivie Page: 1 of 6 Last Review Date: March 18, 2016 Technivie Description Technivie (ombitasvir,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis B / Hepatitis C Peg-interferon Page 1 of 20 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis B / Hepatitis C Peg-interferon Hepatitis
More informationDaklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 4 Last Review Date: September 18, 2015 Daklinza Sovaldi Description
More informationRegulatory Status FDA-approved indication: Tysabri is an integrin receptor antagonist indicated for treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.27 1 of 6 Last Review Date: December 5, 2014 Tysabri Description Tysabri (natalizumab) Background
More informationClinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:
Clinical Policy: (Tysabri) Reference Number: ERX.SPA.162 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More information2. Does the patient have a diagnosis of Crohn s disease? Y N
Pharmacy Prior Authorization MERC CARE PLA (MEDICAID) Stelara (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: November 14, 2018 Effective Date: January 1, 2019 This drug class prior authorization criteria have been
More informationDrug Therapy Guidelines
Simponi, Simponi Aria Applicable Medical Benefit x Effective: 2/13/18 Pharmacy- Formulary 1 x Next Review: 12/18 Pharmacy- Formulary 2 x Date of Origin: 7/2010 Pharmacy- Formulary 3/Exclusive x Review
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cimzia Page: 1 of 5 Last Review Date: March 17, 2017 Cimzia Description Cimzia (certolizumab pegol)
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 5 Last Review Date: March 17, 2017 Xeljanz Description Xeljanz, Xeljanz
More informationClinical Policy: Simeprevir (Olysio) Reference Number: CP.CPA.289 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Olysio) Reference Number: CP.CPA.289 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationDRAFT. Therapeutic Class Code: D6A, S2J, S2M, S2Q, Z2U, Z2Z, S2Z, L1A, S2V, Z2V, D6K Therapeutic Class Description: Injectable Immunomodulators
AFT Therapeutic Class Code: D6A, S2J, S2M, S2Q, Z2U, Z2Z, S2Z, L1A, S2V, Z2V, D6K Therapeutic Class Description: Injectable Immunomodulators Medication Generic Code Number(s) NDC Number(s) Actemra SQ 35486
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other GOLIMUMAB SIMPONI 22533, 22536, 34697, 35001 ROUTE = SUBCUTANE. GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the request for a
More informationAmeriHealth Caritas Iowa Request for Prior Authorization Hepatitis C Treatments
Form applies to IA Health Link and hawk-i plans. Please print accuracy is important. Fax completed form to 1-855-825-2714. Provider Help Desk: 1-855-328-1612. AmeriHealth Caritas Iowa member ID #: Patient
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other CERTOLIZUMAB PEGOL CIMZIA 35554 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the request for a patient with a diagnosis of moderate
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1097-7 Program Prior Authorization/Notification Medication *Stelara (ustekinumab) *This program applies to the subcutaneous formulation
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1041-8 Program Prior Authorization/Notification Medication Humira (adalimumab) P&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009,
More informationHepatitis C Virus Management
Hepatitis C Virus Management FDA-Approved Medications Hepatitis C is caused by a virus and results in liver inflammation, which can lead to advanced liver disease and/or liver cancer. An estimated 3 to
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 5 Last Review Date: March 18, 2016 Xeljanz Description Xeljanz, Xeljanz
More information3. Has the patient shown improvement in signs and symptoms of the disease? Y N
Pharmacy Prior Authorization MERC CARE (MEDICAID) Orencia (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 HUMIRA PEDIATRIC GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the patient currently taking Humira? If
More informationOtezla. Otezla (apremilast) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background
More informationBENEFIT CHANGES TO NBPDP
Bulletin #789 June 15, 2010 BENEFIT CHANGES TO NBPDP This update to the New Brunswick Prescription Drug Program (NBPDP) Formulary is effective June 15, 2010. Included in this bulletin: Regular Benefit
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationCosentyx. Cosentyx (secukinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx
More informationSovaldi Ribavirin. Sovaldi (sofosbuvir) with Ribavirin (Copegus, Moderiba, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Sovaldi Ribavirin Page: 1 of 7 Last Review Date: December 3, 2015 Sovaldi Ribavirin Description
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara
More informationCriteria for Indiana Medicaid Hepatitis C Agents
Prepared for State of Indiana by OptumRx EXECUTIVE SUMMARY Purpose: Promote prudent prescribing of Setting & Population: All members Type of Criteria: Increased Risk of ADE Non-Preferred Agent Appropriate
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 20 Last Review Date: March 16, 2018 Hepatitis C Agents Description
More informationTechnivie. Technivie (ombitasvir, paritaprevir, ritonavir) and Ribavirin. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.37 Subject: Technivie Page: 1 of 6 Last Review Date: December 8, 2017 Technivie Description Technivie
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 19 Last Review Date: December 8, 2017 Hepatitis C Agents
More informationXELJANZ (tofacitinib citrate) oral tablet XELJANZ XR (tofacitinib citrate extended-release) oral tablet
XELJANZ XR (tofacitinib citrate extended-release) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More information2. Has the patient had a response to treatment? Y N. 3. Does the patient have a diagnosis of rheumatoid arthritis (RA)? Y N
12/21/2016 Prior Authorization Aetna Better Health of West Virginia Humira (WV88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationPPHP 2017 Formulary 2017 Step Therapy Criteria
ARISTADA Aristada Prefilled Syringe 1064 MG/3.9ML Intramuscular Aristada Prefilled Syringe 441 MG/1.6ML Intramuscular Aristada Prefilled Syringe 662 MG/2.4ML Intramuscular Aristada Prefilled Syringe 882
More informationPharmacy Medical Necessity Guidelines: Medications for the Treatment of Hepatitis C
Pharmacy Medical Necessity Guidelines: Medications for the Treatment of Hepatitis C Effective: March 13, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.08 Subject: Leukine Page: 1 of 5 Last Review Date: September 15, 2017 Leukine Description Leukine
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 6 Last Review Date: March 16, 2018 Xeljanz Description Xeljanz, Xeljanz
More informationINFECTIOUS DISEASE AGENTS: HEPATITIS C - DIRECT - ACTING ANTIVIRAL
Ohio Department of Medicaid Prior Authorization Form Unified PDL HEPATITIS C TREATMENT Member ID# Patient Name: DOB: Patient Address: Provider DEA: Provider NPI: Provider Name: Phone: Provider Address:
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2052-10 Program Prior Authorization/Medical Necessity Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 4/2015, 8/2015,
More informationClinical Policy: Natalizumab (Tysabri) Reference Number: CP.PHAR.259 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Tysabri) Reference Number: CP.PHAR.259 Effective Date: 07.01.16 Last Review Date: 05.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More informationOlysio Pegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.28 Subject: Olysio Pegasys Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio Pegasys
More informationSimponi / Simponi ARIA (golimumab)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 6 Last Review Date: September 15, 2016 Simponi / Simponi
More informationPRESCRIPTION DRUG PROGRAM FORMULARY UPDATES
PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Generic Additions These generic drugs recently became available in the marketplace. When these generic drugs became available, we began covering them at the
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Multiple Sclerosis Agents (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationC. Assess clinical response after the first three months of treatment.
Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit
More informationSovaldi (sofosbuvir) with PegIntron (peginterferon alfa-2b) and Ribavirin (Copegus, Moderiba, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.24 Subject: Sovaldi PegIntron Ribavirin Page: 1 of 6 Last Review Date: November 30, 2018 Sovaldi PegIntron
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationPharmacy Management Drug Policy
SUBJECT: Inflammatory Conditions Clinical Review Prior Authorization (CRPA) Rx and Medical Drugs POLICY NUMBER: PHARMACY-73 EFFECTIVE DATE: 01/01/2018 LAST REVIEW DATE: 06/11/2018 If the member s subscriber
More informationPegylated Interferon Agents for Hepatitis C
Applicable X X X X X X X Pegylated Interferon Agents for Hepatitis C Override(s) Prior Authorization Quantity Limit Initial for Monotherapy or Combination with Ribavirin based on Genotype, Status, or Co-Infection
More informationClinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: HIM.PA.SP36 Effective Date: Last Review Date: 06.18
Clinical Policy: (Mavyret) Reference Number: HIM.PA.SP36 Effective Date: 08.01.17 Last Review Date: 06.18 Line of Business: HIM Revision Log See Important Reminder at the end of this policy for important
More informationANTIDEPRESSANTS. Details. Step Therapy 2017 Last Updated: 5/23/2017
ANTIDEPRESSANTS EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG FETZIMA CAPSULE
More informationInfergen Monotherapy. Infergen (interferon alfacon-1) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.03 Subject: Infergen Monotherapy Page: 1 of 7 Last Review Date: March 13, 2014 Infergen Monotherapy
More informationAcyclovir Ointment. Aetna Better Health Pennsylvania. Products Affected. acyclovir ointment 5 % external Details. Criteria
Medications that require Step Therapy (ST) require trial and failure of preferred formulary agents prior to their authorization. If the prerequisite medications have been filled within the specified time
More information2. Does the patient have a diagnosis of giant cell arteritis (GCA)? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Actemra (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationOlysio PegIntron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.27 Subject: Olysio PegIntron Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio PegIntron
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Leukine Page: 1 of 6 Last Review Date: November 30, 2018 Leukine Description Leukine (sargramostim)
More information3. Is the prescribed dose within the Food and Drug Administration (FDA)- approved dosing for giant cell arteritis?
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Actemra (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More information2018 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1127-9 Program Prior Authorization/Notification Medication Sovaldi (sofosbuvir) P&T Approval Date 2/2014, 4/2014, 5/2014, 8/2014,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tysabri) Reference Number: HIM.PA.SP17 Effective Date: 05.01.17 Last Review Date: 05.18 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH VIRGIIA Multiple Sclerosis Agents (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More information